AlphAIalphai — Financial news for AI agents
simplywall.stAUG 252 min read$HROW

Harrow (HROW) Reported Positive IHEEZO Study Results In Intravitreal Injections

Harrow (HROW) announced positive clinical study results for its IHEEZO ophthalmic gel, showing reduced patient discomfort during intravitreal injections. The study is relevant for Harrow's focus on specialty eye care and may impact its revenue mix. Investors will watch for real-world adoption in retina practices.

Original reporting
simplywall.st
Published Aug 25, 2026, 2:44 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 25, 2026, 8:44 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefTechnology
Primary signal
$HROW
Bullish
medium confidence
Mentioned
$HROW
Relevance
8/10
alphai data visualization · based on simplywall.st
Decision brief

The 30-second read

$HROWBullishMed
01

Why it matters

Positive data supports Harrow's narrative but does not resolve reliance on a few flagship products.

02

Market read

First report of trial data; could influence Harrow's stock and related eye‑care biotech peers.

03

What to watch

Pricing negotiations and competition from existing intravitreal drugs could dampen impact.

Relevance 8/10Novelty 8/10Timing: today

Background

Harrow focuses on specialty ophthalmic products; IHEEZO aims to improve patient comfort during high‑volume retinal procedures.

Company-level read

Ticker impact

$HROWBullishMedium confidence
Context

Harrow reported positive Phase 2 clinical trial results for its IHEEZO ophthalmic gel used in intravitreal injections.

Expected impact

Potential modest upside as investors price in improved product profile.

Evidence & confidence

First disclosure of statistically significant comfort reductions; biotech trials often move price on initial release.

Market effects

Sector

May boost sentiment for ophthalmic and eye‑care biotech segment.

Regional

US biotech sector could see slight lift.

Global

Limited to niche eye‑care market.

Counterpoint

What could challenge this read

Trial results may not translate to commercial adoption; payer pressure could limit upside.

Key entities

  • Company
    Harrow

    US‑based ophthalmic pharmaceutical company.

Read at source← All news

Related articles

AUG 21
$HROWMedAI 8/10

What's Going On With Harrow Stock Friday? - Harrow (NASDAQ:HROW)

Harrow Inc. (NASDAQ:HROW) reported positive results from a clinical study of its ocular anesthetic IHEEZO, showing significant pain reduction compared to a control. Analysts noted the findings support long-term growth and maintained an Outperform rating. HROW shares were down 1.33% at $41.50 on Friday.

benzinga.com2 min
AUG 20
$HROWMed

Harrow (HROW): Strong Product Momentum Meets A Steep H2 Revenue Target

Harrow Inc. (HROW) reported H1 2026 revenue of $115M, below expectations, but reaffirmed its full-year guidance of $350M-$365M. Key products IHEEZO, VEVYE, and TRIESENCE showed strong growth, but the company faces a steep H2 revenue target. Harrow also announced a pending deal for TYRVAYA, expected to add $30M in 2027 revenue. Adjusted EBITDA was negative $1.2M for the quarter, and the company has $83.9M in cash.

yahoo.com2 min
AUG 13
$HROWMed

Harrow Q2 Earnings Call Highlights

Harrow (NASDAQ:HROW) reported Q2 revenue of $15.6M for IHEEZO, with demand up to 65,477 units (+44% sequential, +34% YoY) but revenue lagging due to distributor sell-through of prior inventory. Management cited normalized channel inventory, ~25% higher net pricing effective July 1, gross margin 71%, and cash of $83.9M. Harrow also discussed BYOOVIZ launch, VEVYE PBM coverage, and a pending TYRVAYA acquisition.

yahoo.com6 min
AUG 10
$HROWMed

HARROW, INC. (HROW): Results of Operations and Financial Condition

HARROW, INC. (HROW) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Harrow Announces Second Quarter 2026 Financial Results Second Quarter 2026 and Selected Highlights: ● Quarterly revenue of $70.7 million, an increase of 60% sequentially, and 11% year over year ● Reiterated full-year 2026 financial guidance of $350 million to $365 mi

SEC EDGAR 8-K7 min
JUL 1
$HROWMed

Harrow Announces Commercial Launch of BYOOVIZ® in the United States

Harrow (Nasdaq: HROW) announced the U.S. commercial launch of BYOOVIZ (ranibizumab-nuna), an FDA-approved interchangeable biosimilar referencing Lucentis, for wet AMD, RVO macular edema, and mCNV. The launch follows Harrow’s exclusive U.S. commercialization agreement with Samsung Bioepis. Harrow also noted exclusive U.S. rights to OPUVIZ (aflibercept-yszy).

manilatimes.net4 min